Flagship Wealth Advisors LLC Takes $420,000 Position in Pfizer Inc. (NYSE:PFE)

Flagship Wealth Advisors LLC purchased a new stake in Pfizer Inc. (NYSE:PFE) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 15,820 shares of the biopharmaceutical company’s stock, valued at approximately $420,000.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Swedbank AB increased its stake in Pfizer by 0.7% during the 3rd quarter. Swedbank AB now owns 5,745,831 shares of the biopharmaceutical company’s stock valued at $166,284,000 after buying an additional 37,636 shares during the period. United Bank increased its position in shares of Pfizer by 3.7% in the third quarter. United Bank now owns 35,599 shares of the biopharmaceutical company’s stock worth $1,030,000 after acquiring an additional 1,277 shares in the last quarter. Vaughan Nelson Investment Management L.P. increased its position in shares of Pfizer by 15.4% in the third quarter. Vaughan Nelson Investment Management L.P. now owns 88,670 shares of the biopharmaceutical company’s stock worth $2,566,000 after acquiring an additional 11,820 shares in the last quarter. Spinnaker Investment Group LLC increased its position in shares of Pfizer by 7.0% in the third quarter. Spinnaker Investment Group LLC now owns 8,249 shares of the biopharmaceutical company’s stock worth $239,000 after acquiring an additional 541 shares in the last quarter. Finally, Atlanta Consulting Group Advisors LLC boosted its holdings in shares of Pfizer by 274.5% during the third quarter. Atlanta Consulting Group Advisors LLC now owns 46,786 shares of the biopharmaceutical company’s stock worth $1,354,000 after purchasing an additional 34,293 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Price Performance

Shares of PFE opened at $25.74 on Monday. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The business’s 50 day moving average price is $26.24 and its two-hundred day moving average price is $27.12. The firm has a market cap of $145.85 billion, a PE ratio of 18.25, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. During the same quarter in the previous year, the firm earned $0.10 earnings per share. The business’s revenue was up 24.7% on a year-over-year basis. On average, equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on PFE shares. Citigroup reduced their target price on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a research report on Wednesday, March 12th. StockNews.com lowered shares of Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. Truist Financial lowered their price target on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. Finally, Bank of America restated a “neutral” rating and issued a $29.00 target price on shares of Pfizer in a research note on Tuesday, December 10th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $31.92.

Insider Activity

In other Pfizer news, Director Ronald E. Blaylock bought 19,457 shares of the firm’s stock in a transaction on Thursday, February 13th. The shares were acquired at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the purchase, the director now directly owns 27,707 shares of the company’s stock, valued at $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.06% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.